News

Caretaker Medical Awarded the Grand Prize in NIH RADx Tech for Maternal Health Challenge

Caretaker Medical, a digital health company focused on developing hemodynamic monitoring devices, today announced that it has been awarded the $525,000 grand prize in the US National Institutes of Health (NIH) Rapid Acceleration of Diagnostics Technology for Maternal Health Challenge. The award recognizes Caretaker’s wireless, wearable wrist device, VitalStream, that can be used to monitor postpartum women for episodes of hyper- or hypotension, as well as detect the early onset of hemorrhage and sepsis. VitalStream continuously measures heart rate, blood pressure, respiration, cardiac output and stroke volume, among other vital signs.

In the US, over 80% of pregnancy-related deaths are preventable. And in 2020, 36% of deaths occurred 1-42 days postpartum. Continuous monitoring can help clinicians detect clinical decompensation sooner. A noninvasive, wireless monitor can expand advanced monitoring capabilities to more women and can potentially even be worn after hospital discharge.

“We are honored to receive this award and to be recognized for VitalStream’s potential to impact maternal health outcomes,” stated Jeff Pompeo, President and CEO of Caretaker Medical. “VitalStream can offer clinicians the continuous data they need to intervene earlier, potentially save the lives of new mothers.”

The RADx challenge prioritized technologies that are innovative, easy to use and can be used to help reduce health disparities.

For more information or to schedule a demonstration, contact Caretaker Medical.

Read more here.

Recent News

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and

06/02/2026

Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development

Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, today announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. In conjunction with the closing of the Series B financing,

06/02/2026

GEN Names BioHealth Capital Region a Top 3 U.S. Biopharma Cluster for Fourth Year in a Row

The BioHealth Capital Region, spanning Maryland, Virginia, and Washington, D.C., has once again been named one of the nation’s Top 3 biopharma clusters by Genetic Engineering & Biotechnology News (GEN), marking the region’s fourth consecutive year in the Top 3. GEN’s 2026 “Top 10 U.S. Biopharma Clusters” ranking was authored by Alex Philippidis, Senior Business